Heart Failure, Diastolic, Heart Failure, Systolic, Overweight and Obesity, Peripheral Arterial Disease
Conditions
Brief summary
The purpose of the study is to determine associations between fitness status, bacteria in the mouth, and the blood flow to muscle. This study is trying to find out if fitness status impacts the bacteria that are present in the oral microbiome (environment in the mouth) or the ability of the body to send blood to the skeletal muscle. Participants will complete all or some of the following: * A mouth swab to assess the bacteria in their mouths. * Produce a saliva sample into a tube. * Cycle on a bike until you reach maximum effort. * Undergo blood draws * Wear a 24-hour non-invasive device that monitors blood pressure. * Drink 70mL (1/3 of a cup) of concentrated beetroot juice once
Detailed description
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. Nitric oxide (NO) is a gaseous diatomic free-radical and is essential for a plethora of physiological functions involved in cardiometabolic health and CVD risk. NO bioavailability is associated with greater tissue perfusion, mitochondrial function, glucose regulation, and overall reduced CVD risk. The primary source of circulating NO is vascular endothelial nitric oxide synthase. Unfortunately, the endothelium can be disrupted/damaged via a variety of CVD risk factors such as hypertension, smoking, hyperlipidemia, diabetes, inflammation, and hypercholesteremia. Disruption of the vascular endothelium and loss of bioavailable NO is a preliminary step in the progression of atherosclerosis and CVD. Decreased NO bioavailability and vascular dysfunction have been shown in a variety of clinical conditions including patients heart failure and peripheral artery disease (PAD). Recently, an exogenous approach to increasing NO bioavailability via oral supplementation of inorganic nitrate (NO3-) has been utilized to increase NO bioavailability in various healthy and clinical populations. Briefly, inorganic NO3- is swallowed, absorbed into the circulation, and sequestered back into the salivary glands. NO3- is then secreted into the oral cavity, where bacteria containing nitrate reductase enzymes convert NO3- to nitrite (NO2-), which is again swallowed and absorbed into the circulation. NO2- in the plasma is then easily reduced to NO via non-enzymatic reactions. This study aims to better elucidate the relationship between the oral microbiome abundance and diversity and NO3- to NO2- to NO conversion across a variety of subject populations ranging from healthy subjects to those with risk factors for CVD and people with diagnosed CVD. We also aim to examine the relationship between oral microbiome NO3- reduction and impaired skeletal muscle perfusion and exercise capacity as NO bioavailability plays a large role in these physiological processes. The results of this study may allow us to better understand how novel interventions to modify the oral microbiome may improve cardiometabolic health and physical function in individuals with CVD and outline potential new therapeutic approaches. The primary objective of this preliminary study is to compare the abundance and diversity of oral NO3- reducing bacteria in a variety of subjects with varying cardiometabolic health status and their ability to convert oral inorganic nitrate to nitrite measured in the saliva and plasma.
Interventions
None listed
Sponsors
University of Virginia
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent. * Subjects may be of either sex with age 18 years.
Exclusion criteria
* Oral antibiotic use within previous four weeks * Oral disease or poor oral health as determined by the Oral Health Questionnaire * Using an antibacterial mouthwash or a mouthwash containing chlorhexidine and unwilling to discontinue use * Tobacco smokers * Pregnant or lactating females * Hypersensitivity to any ultrasound contrast agent * Inability to perform exercise * Unable to communicate effectively in English to the study team. * Diagnosis of chronic renal failure (GFR \< 60 ml/min/1.73m) * Subjects taking nitroglycerine (or inorganic nitrates), PDE-5 inhibitors (ex: Cialis, Viagra), and xanthine oxidase inhibitors (ex: Allopurinol).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oral Nitrate Reducing Capacity | Baseline, 4-weeks, 12-weeks, 6-months | Assessment of the oral microbiome's ability to reduce nitrate to nitrite. This will be measured through a swab on the dorsal surface of the tongue, an unstimulated saliva sample, and a rinse of a standard nitrate solution. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Aerobic Capacity | Baseline, 4-weeks, 12-weeks, 6-months | Peak aerobic capacity (VO2peak) will be assessed using a symptom-limited graded exercise test on a cycle ergometer. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Flow-Mediated Dilation | Baseline, 4-weeks, 12-weeks, 6-months | Participants will be placed in a supine position with their left forearm slightly extended and supinated with legs straight. The arteries will be imaged using a high-resolution 7.5MHz linear array transducer at rest, during 5 minutes of forearm occlusion via cuff inflation, and continuously for 3 minutes post-occlusion; an EKG trigger will be used to capture images during end-diastole of the cardiac cycle. |
| Serum Glucose | Baseline, 4-weeks, 12-weeks, 6-months | A blood sample will be obtained to measure serum glucose. |
| Insulin | Baseline, 4-weeks, 12-weeks, 6-months | A blood sample will be obtained to measure insulin. |
| Lipids | Baseline, 4-weeks, 12-weeks, 6-months | A blood sample will be obtained to measure lipids. |
| Peripheral and Central Blood Pressures | Baseline, 4-weeks, 12-weeks, 6-months | Brachial artery blood pressures will be obtained using a standard sphygmomanometer. Aortic blood pressures will be obtained using applanation tonometry (SphygmoCor version 8.0, AtCor Medical). |
| Hematocrit | Baseline, 4-weeks, 12-weeks, 6-months | A blood sample will be obtained to measure hematocrit. |
| Plasma Nitrate | Baseline, 4-weeks, 12-weeks, 6-months | A fasting blood draw will be taken. Following the blood draw, the participant will take one dose of Beetroot juice. The participant will then return to the lab three hours later for a second blood draw to assess level of nitrate in the plasma. |
| Plasma Nitrite | Baseline, 4-weeks, 12-weeks, 6-months | A fasting blood draw will be taken. Following the blood draw, the participant will take one dose of Beetroot juice. The participant will then return to the lab three hours later for a second blood draw to assess level of nitrite in the plasma. |
| Hemoglobin | Baseline, 4-weeks, 12-weeks, 6-months | A blood sample will be obtained to measure hemoglobin. |
| 24-hour ambulatory blood pressure | Baseline, 4-weeks, 12-weeks, 6-months | Blood pressure will be monitored using a standard ambulatory brachial artery blood pressure cuff (SunTech Oscar 2, SunTech Medical). Blood pressure measurements are programmed to be taken every 30-minutes during the day and every hour at night. This allows for monitoring of nighttime blood pressure changes and variations throughout the day. |
Countries
United States
Contacts
Primary ContactCasey C Derella, PhD
Backup ContactMacy E Stahl, B.S.E.d
Outcome results
None listed